Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026 On Track to Initiate Second Phase 3 Study, ...

Japanese registry data point to fewer deaths and heart failure hospitalizations, especially when MR is reduced to mild or ...

For the first time, a scientific statement on prevention of heart failure has been released. The statement from the Heart ...

Heart failure (HF) remains a significant cardiovascular public health concern in India, affecting an estimated 1.3 to 22.7 ...

Novo Nordisk (($DE:NOVA)) announced an update on their ongoing clinical study. Novo Nordisk is conducting a Phase 2 study titled ‘A Research Study ...

Cardiosense says its CardioTag device is the first wearable sensor that simultaneously captures high-fidelity ECG, PPG and SCG signals ...

There is lower risk for recurrent HF hospitalization in older patients that receive SGLT2is following acute decompensated heart failure.

After positive trial results for TX45, Tectonic Therapeutic is planning a Phase 2 study to test its effects on blood flow in ...

Key Points GAAP revenue surged to $66.8 million in Q2 2025, driven by recognition of one-time license and milestone payments, exceeding analyst estimates by 3,065.9% (GAAP). GAAP loss per share ...

US-based Cardurion Pharmaceuticals has completed enrolment in two multi-centre, global Phase II CYCLE trials of the ...

Early symptoms like fatigue, breathlessness, swelling mimic common heart issues, causing cardiac amyloidosis to go undetected ...

A new study published in the European Journal of Medical Research revealed that dapagliflozin, a sodium-glucose ...